HC Wainwright Estimates Biodesix’s Q2 Earnings (NASDAQ:BDSX)

Biodesix, Inc. (NASDAQ:BDSX) – Equities researchers at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Biodesix in a research note issued to investors on Monday, June 15th. HC Wainwright analyst Y. Chen forecasts that the company will earn ($0.81) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Biodesix’s Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.87) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.65) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.36) EPS and FY2027 earnings at ($2.00) EPS.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.32. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. The firm had revenue of $25.56 million for the quarter, compared to the consensus estimate of $23.12 million.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Canaccord Genuity Group upped their price objective on shares of Biodesix from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a research note on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Biodesix Stock Performance

Shares of Biodesix stock opened at $15.33 on Wednesday. The company has a debt-to-equity ratio of 5.09, a current ratio of 2.82 and a quick ratio of 2.82. Biodesix has a one year low of $5.00 and a one year high of $20.21. The business has a 50-day simple moving average of $14.10 and a 200 day simple moving average of $12.11. The firm has a market capitalization of $158.82 million, a price-to-earnings ratio of -3.78 and a beta of 0.59.

Institutional Investors Weigh In On Biodesix

A number of hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC purchased a new position in Biodesix in the first quarter valued at approximately $10,996,000. Aberdeen Group plc bought a new stake in shares of Biodesix in the fourth quarter valued at $1,784,000. XTX Topco Ltd raised its stake in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares during the period. Monashee Investment Management LLC lifted its position in shares of Biodesix by 12.3% during the 4th quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock valued at $764,000 after buying an additional 12,348 shares during the last quarter. Finally, Stempoint Capital LP bought a new position in shares of Biodesix during the 1st quarter worth $1,015,000. Institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.